anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, pharmacy. SUBSTANCE: invention proposes the drug that is the composition showing synergistic, biological, neurometabolic and providing cellular trophism and also etiopathogenic and homeostatic effects. Composition is developed on the basis of combination the following active components: (a) with respect to oxidative and catabolic stress: methionine with aminoethanolphenoxy acetates and/or aminoethylphenoxy acetamides; (b) with respect to anabolic stress: hydrooxopyrimidine carboxylates and/or oxopyrrolidine acetamides with potassium, zinc or lithium; (c) vasodilating and lipidemia normalizing preparations: nicotinic alcohol and/or acid or their derivatives with magnesium and iodine; (d) energy activating and (e) antitoxic compounds: aspartate, fructose, vitamin B 1 , vitamin B 6 , hydroorthophosphate and sulfate. Method of preparing the drug involves the following stages: (a) pharmaceutical preparing two complementary types of capsules or tablets with cover that are soluble in stomach and intestine being the latter have enterosoluble envelope; (b) prolonged release of vasodilating preparation from intestine-soluble standard dose. Invention provides emotional-affective stabilization and maintenance of human mental functions under stress conditions. EFFECT: improved method of preparing, enhanced effectiveness of drug. 7 tbl, 3 ex
Deviations from a clinical trial protocol are identified based on automated analysis of clinical trial data. Clinical trial data can be collected for subjects or investigators at multiple study sites using any number of systems or collection methods. The types of data to be analyzed can be defined by identifying aspects of conducting a clinical trial which are imperative to maintaining integrity of the clinical trial data. Rules can be defined based on the identified critical aspects to establish criteria to be satisfied to ensure that the clinical trial has been conducted according to the protocol. A cross-database analysis of clinical trial data is performed to determine whether deviations have occurred. Deviations are logged for subsequent analysis to determine whether the deviation is part of a greater trend in errors. The associated clinical trial data can be further evaluated and the clinical trial workflow directed to address the identified errors.
The use of highly active antiretroviral therapy (HAART) has resulted in a significant reduction in AIDS-related deaths and complications among adults and adolescents. However, the medical management of HIV infected children remains challenging. Access to HIV treatment is limited and early treatment initiation can cause serious complications. Since there is currently no cure for HIV, a balance between treating the disease and maintaining quality of life must be weighed carefully. An evaluation to determine the appropriate time to initiate HAART is necessary to improve both quality of life and survival for HIV infected children.

This study will last 144 weeks. All participants will have a CD4 percentage (CD4%) between 15% and 24% and will be randomly assigned to either receive immediate or delayed HAART. The HAART regimen will consist of two nucleoside reverse transcriptase inhibitors, zidovudine and lamivudine. In addition, participants will also receive either one non-nucleoside reverse transcriptase inhibitor, nevirapine or efavirenz, or one protease inhibitor, ritonavir-boosted lopinavir or nelfinavir. Abacavir will replace zidovudine or lamivudine if participants experience toxicity to the regimen. Participants in the immediate treatment arm will receive HAART on Day 1 of the study regardless of their CD4%. Participants in the delayed treatment arm will receive HAART if their CD4% falls below 15 or if they develop a CDC Category C illness.

Study visits will occur every 4 weeks for the first 12 weeks and then every 12 weeks until the end of the study. Blood collection, physical exams, and medical and medication history reviews will occur at all visits. Adherence, quality of life, and lipodystrophy assessments will occur every 12 weeks for participants on HAART. Participants will be encouraged to enroll in a related substudy to examine the neurodevelopment of HIV infected children.
The approach is to conduct a randomized, cross-over trial in a controlled human laboratory setting with healthy volunteers (n=22). After obtaining informed consent, eligible participants will be scheduled for 3 separate two-night test days to receive 0.15mg IV, 8mg PO, or 16mg PO of buprenorphine. The first dose administered will be fixed to an open-label IV dose, and the subsequent doses will be randomized and counterbalanced to 8mg or 16mg PO. Visits will be scheduled at least 1 week apart to allow for washout of drug. One hour prior to receipt of the buprenorphine dose, all participants will be fed a standardized light breakfast. The IV dose will be given after establishing IV access, while the PO doses will be swallowed whole. Participants will also receive oral naltrexone 100mg 24 hours prior to each dosing to provide blockade at the mu-receptor, as well as 50mg PO at the study visit itself prior to receipt of buprenorphine. Timed blood samples will be collected in heparinized Vacutainer tubes via a catheter in the antecubital vein at baseline, and at 0.5, 1, 2, 4, 8, and 24 hours. Samples will be centrifuged and frozen until analysis.
This study aims to visualize publications related to venous thromboembolism (VTE) and lower limb joint arthroplasty to identify research frontiers and hotspots, providing references and guidance for further research. We retrieved original articles published from 1985 to 2022 and their recorded information from the Web of Science Core Collection. The search strategy used terms related to knee or hip arthroplasty and thromboembolic events. Microsoft Excel was used to analyze the annual publications and citations of the included literature. The rest of the data were analyzed using the VOSviewer, citespace and R and produced visualizations of these collaborative networks. We retrieved 3543 original articles and the results showed an overall upward trend in annual publications. The United States of America had the most significant number of publications (Np) and collaborative links with other countries. McMaster University had the greatest Np. Papers published by Geerts WH in 2008 had the highest total link strength. Journal of Arthroplasty published the most articles on the research of VTE associated with lower limb joint arthroplasty. The latest research trend mainly involved "general anesthesia" "revision" and "tranexamic acid." This bibliometric study revealed that the research on VTE after lower limb joint arthroplasty is developing rapidly. The United States of America leads in terms of both quantity and quality of publications, while European and Canadian institutions and authors also make significant contributions. Recent research focused on the use of tranexamic acid, anesthesia selection, and the VTE risk in revision surgeries.
Risk Summary

There are no data on the presence of cipaglucosidase alfa-atga, alone or in combination with miglustat, in human milk, the effects on the breastfed infant, or the effects on milk production. Cipaglucosidase alfa‑atga is present in animal milk (see Data). When a drug is present in animal milk, it is likely that the drug will be present in human milk. Based on findings in animal studies, the use of POMBILITI in combination with Opfolda may lead to serious adverse reactions in breastfed infants. Advise females that breastfeeding is not recommended while on treatment with POMBILITI in combination with Opfolda.

Data

Evaluation of milk in rats from the pre- and post-natal development study of cipaglucosidase alfa atga in combination with miglustat (400 mg/kg and 60 mg/kg, respectively) showed excretion of cipaglucosidase alfa-atga and secretion of miglustat in rat milk. In this study, the ratio of cipaglucosidase alfa-atga exposure in rat milk to cipaglucosidase alfa-atga exposure in rat plasma was <4%, and the ratio of miglustat exposure in rat milk to the miglustat exposure in rat plasma was 1.7.  
The concentration of drug in animal milk does not necessarily predict the concentration of drug in human milk.
Nutri VX1 in a single dose (1 sequence of 10 tablets). Nutri VX1 is a complex of trace elements with the status of a food supplement.
The study will include Type 2 Diabetics who are taking only oral hypoglycemic medications (without insulin). Their therapy has to be stable for at least 3 months prior enrollment. Besides anthropometric measures, patient's glycaemia, renal and liver function will be monitored. Safety and adverse events will be closely monitored and these are the primary outcomes of the study. The main outcome measure of the effectiveness is HbA1c (glycated hemoglobin). Patients will be given detailed instructions on how to prepare the tea and the dosing. The intervention will last 3 months and during that time patients will be asked not to change their dietary or lifestyle habits.
PURPOSE: The present retrospective study aimed to analyze patient characteristics, perioperative complications, and short-term outcomes of surgery for fragility fractures of the pelvis (FFP).
METHODS: We selected 42 patients who underwent surgery for FFP between October 2019 and October 2022 and could be followed for more than 6 months postoperatively, including one male patient and 41 female patients with an average age of 83.5 (65-96) years. The following demographic data were collected: Rommens classification, surgical method, reoperation rate, implant loosening, perioperative complications, interventional radiology (IVR) indication rate, perioperative blood transfusion indication rate, Parker Mobility Score (PMS) before surgery and at final follow-up, and numerical rating scale (NRS) score before surgery and on day 3 postoperatively.
RESULTS: Rommens classification was as follows: type IIa (n = 2), type IIb (n = 13), type IIIa (n = 8), type IIIc (n = 3), type IVb (n = 13), and type IVc (n = 3). For surgical procedure, 35 patients (83.3%) were successfully stabilized with percutaneous screw fixation alone, and 7 patients further required open plate fixation. Implant loosening was observed in 16 patients (38.1%), including minor cases, and implant removal was required in 1 patient. Minor perforation of the screw was observed as an intraoperative complication in 6 patients; there were no patients with neurological symptoms. At the time of injury, IVR was indicated in 3 patients (7.1%) because of hemorrhage. Thirty patients (71.4%) had medical complications at the time of admission. One patient died due to postoperative pneumonia. Mean PMS before injury and at final follow-up were 6.51 points and 5.38 points, respectively. Mean NRS scores before surgery and on day 3 postoperatively were 5.26 and 3.49, respectively, showing a significant improvement (p < 0.01).
CONCLUSION: We retrospectively reviewed 42 patients who required surgery for FFP. More than 80% of cases could be treated with percutaneous screw fixation, but it is always important to consider hemorrhagic shock at the time of injury and indications for IVR. Implant loosening was observed in 38.1% of patients, including minor cases, and was considered an issue to be improved on in the future, such as by using cement augmentation. A significant improvement in mean NRS score on day 3 postoperatively relative to the mean preoperative score was observed, suggesting that surgery may contribute to early mobilization.
The invention consisting of a segmented releasing device (sandwich construction with a reservoir) for molecules (active substances, medicaments, diagnostic, therapeutic and chemical reagents) is based upon a construction that enables a constant release rate though diffusion-permeable intersegment films partially or completely filled with liquid of the adjoining media. The molecules exit the reservoir of the device by diffusion solely via the intersegment films whereby passing into the outer medium. The thickness and composition of these intersegment films can be adjusted in respectively given manner. The release rate can be determined in advance within broad limits by the structure and geometry of the segmented device and by the number, composition and dimensions of the thin intersegment films and can also be calculated. The inventive device makes it possible to set an extraordinarily precise release rate of the molecules. This enables an optimal adaptation to the respectively existing release function of the formulation. With regard to the molecules, only the knowledge of the solubility and of the diffusion coefficients are of essential importance. The shape of the segments makes it possible to achieve a directional dependence of the release. Areas, which are near the reservoir, have a shorter diffusion distance than areas located further away. The release capacity can approximately reach the capacity of the reservoir.
Verapamil Hydrochloride Extended-release Capsules (PM) capsules may also be administered by carefully opening the capsule and sprinkling the pellets onto one tablespoonful of applesauce. Swallow the applesauce immediately without chewing and follow with a glass of cool water to ensure complete swallowing of the pellets. The applesauce used should not be hot and it should be soft enough to be swallowed without chewing. Use any pellet/applesauce mixture immediately and do not store for future use. Absorption of the pellets sprinkled onto other foods has not been tested. This method of administration may be beneficial for patients who have difficulty swallowing whole capsules. Subdividing the contents of a Verapamil Hydrochloride Extended-release Capsules (PM) capsule is not recommended.
Obesity has reached global epidemic proportions, and even though its effects are well-documented, studying the interactions among all influencing factors is crucial for a better understanding of its physiopathology. In a high-fat-diet-induced obesity animal model using C57BL/6J mice, behavioural responses were assessed through a battery of tests, while stress biomarkers and systemic inflammatory cytokines were measured using an Enzyme-Linked ImmunoSorbent Assay and a Bio-Plex Multiplex System. The peritoneal macrophage microbicide capacity was analysed via flow cytometry, and crown-like structures (CLSs) in white adipose tissue (WAT) were evaluated through staining techniques. Results indicated that obese mice exhibited increased body weight, hyperglycaemia, and hyperlipidaemia after 18 weeks on a high-fat diet, as well as worse physical conditions, poorer coordination and balance, and anxiety-like behaviour. Differences in corticosterone and noradrenaline concentrations were also found in obese animals, revealing a stress response and noradrenergic dysregulation, along with a weakened innate immune response characterized by a lower microbicide capacity, and the presence of an underlying inflammation evidenced by more CLSs in WAT. Altogether, these findings indicate that obesity deteriorates the entire stress, inflammatory, metabolic, sensorimotor and anxiety-like behavioural axis. This demonstrates that jointly evaluating all these aspects allows for a deeper and better exploration of this disease and its associated comorbidities, emphasizing the need for individualized and context-specific strategies for its management.
Endometriosis is a benign inflammatory onco-mimetic disease affecting 10-15% of women in the world. When it is refractory to medical treatments, surgery may be required. Usually, laparoscopy is the preferred approach, but robotic surgery has gained popularity in the last 15 years. This study aims to evaluate the safety and efficacy of robotic-assisted laparoscopic surgery (RAS) versus conventional laparoscopic surgery (LPS) in the treatment of endometriosis. This study adheres to PRISMA guidelines and is registered with PROSPERO. Studies reporting perioperative data comparing RAS and LPS surgery in patients with endometriosis querying PubMed, Google Scholar and ClinicalTrials.gov were included in the analysis. The Quality Assessment of Diagnostic Accuracy Studies 2 tool (QUADAS-2) was used for the quality assessment of the selected articles. Fourteen studies were identified, including 2709 patients with endometriosis stage I-IV for the meta-analysis. There were no significant differences between RAS and LPS in terms of intraoperative and postoperative complications, conversion rate and estimated blood loss. However, patients in the RAS group have a longer operative time (p < 0.0001) and longer hospital stay (p = 0.020) than those in the laparoscopic group. Robotic surgery is not inferior to laparoscopy in patients with endometriosis in terms of surgical outcomes; however, RAS requires longer operative times and longer hospital stay. The benefits of robotic surgery should be sought in the easiest potential integration of robotic platforms with new technologies. Prospective studies comparing laparoscopy to the new robotic systems are desirable for greater robustness of scientific evidence.
Provided is hair treating agent capable of permanent waving hair even at a neutral to weakly acidic pH range that causes less irritation to the skin, and hair treating agents in which an unpleasant odor is masked. The hair treating agent contains at least one compound represented by the formula (2). The hair treating agent contains a compound of the formula (2) and at least one compound (ii) selected from thioglycolic acid, thiolactic acid, cysteine, acetylcysteine, cysteamine, acylcysteamine, salts thereof and ester derivatives thereof. The hair treating agent contains a compound of the formula (2), a surfactant and water, and is emulsified. The hair treating agent contains a compound of the formula (2) and a specific perfume. (wherein X is a structure selected from -O-, -S-, -NH- and -NR1-; R1 is an alkyl group of 1 to 6 carbon atoms; Y is an oxygen atom or a sulfur atom; in the formula (1), Z is a divalent organic residue having at least one mercapto group; in the formula (2), R is a divalent organic residue optionally having a mercapto group; and R2 is a hydrogen atom or an alkyl group of 1 to 6 carbon atoms.)
BACKGROUND: Most questionnaires provide little information about children's or parents' views on functioning and do not attempt to understand their priorities or expectations. The Gait Outcomes Assessment List (GOAL) questionnaire was developed to fill this gap by identifying the most important goals of the patient and family for a gait intervention.
RESEARCH QUESTION: To investigate the test-retest reliability and concurrent and discriminant validity of the GOAL questionnaire in children with cerebral palsy (CP) in Türkiye.
METHODS: In this study, we included 81 children with CP aged 5-18 years and their families. The parent and child version 5.0 of the GOAL was used. Standardized item, domain and total (across all domains) GOAL scores were calculated for each participant. Test-retest reliability was assessed with the intraclass correlation coefficient (ICC). The Gillette Functional Assessment Questionnaire (FAQ) was used for validation.
RESULTS: The mean age of the children was 10.4 ± 3.3 years (range 5-18), and 64.2 % were boys. The test-retest reliability was excellent for the GOAL-Child and GOAL-Parent total GOAL scores (ICC: 0.97 for the child and ICC: 0.96 for the parent). All standard errors of measurement (SEMs) for domain scores and total scores were fewer than 20 points. The children's total scores on the GOAL questionnaire showed a significant difference between the GMFCS levels (p <0.001). The parents' total scores on the GOAL questionnaires also showed a significant difference between the GMFCS levels (p <0.001). There were moderate positive correlations between the GOAL child and parent questionnaire total scores and the FAQ walking level according to Spearman's rho (GOAL child and FAQ walking rho: 0.66, p<0.001; GOAL parent and FAQ walking rho: 0.58, p<0.001).
SIGNIFICANCE: The results demonstrate that the child and parent versions of the GOAL 5.0 are valid and reliable for the comprehensive assessment of Turkish children with CP.
Safety and effectiveness of RELPAX Tablets in pediatric patients have not been established; therefore, RELPAX is not recommended for use in patients under 18 years of age. 

The efficacy of RELPAX Tablets (40 mg) in patients 11–17 was not established in a randomized, placebo-controlled trial of 274 adolescent migraineurs (see CLINICAL STUDIES). Adverse events observed were similar in nature to those reported in clinical trials in adults. Postmarketing experience with other triptans includes a limited number of reports that describe pediatric patients who have experienced clinically serious adverse events that are similar in nature to those reported rarely in adults. Long-term safety of eletriptan was studied in 76 adolescent patients who received treatment for up to one year. A similar profile of adverse events to that of adults was observed. The long-term safety of eletriptan in pediatric patients has not been established.
Oral cephalexin (available in capsule or suspension format) dosed at 150 mg/kg/day. Doses will be administered 3 times a day for 2 weeks.
PCT No. PCT/SE96/00570 Sec. 371 Date Jan. 5, 1998 Sec. 102(e) Date Jan. 5, 1998 PCT Filed May 2, 1996 PCT Pub. No. WO96/34893 PCT Pub. Date Nov. 7, 1996Hybrid molecules between heat-labile enterotoxin B subunit (LTB) and cholera toxin B subunit (CTB) are disclosed. Such a hybrid molecule comprises an amino-acid sequence which is composed of the amino-acid sequence of mature CTB in which such amino-acid residues are substituted with the corresponding amino-acid residues of mature LTB which impart LTB-specific epitope characteristics to said immunogenic mature CTB, or vice versa. In addition, a structural gene coding for such a hybrid molecule, a plasmid containing such a structural gene, and an immunogenic protein comprising such a hybrid molecule and optionally an immunoreactive amino-acid sequence of a prokaryotic or eukaryotic cell or a virus, are disclosed. Disclosed is also a vaccine, e.g. against enterotoxin-induced illness, comprising such an immunogenic protein, and a method of preventing or treating enterotoxin-induced illness in an individual.
Significant pharmacokinetic variation occurs in critically ill patients, leading to underexposure to antibiotics and poor prognosis. In this study, we developed a simple, sensitive, and fast liquid chromatography tandem mass spectrometry (LCMS/MS) platform for the simultaneous quantification of 8 antibacterial and 2 antifungal drugs, which is optimally suited for clinically efficient, real-time therapeutic drug monitoring (TDM). Multiple reaction monitoring (MRM) mass spectrometry was used in this method, and samples were prepared via protein precipitation with methanol. Chromatographic separation was accomplished on a BGIU Column-U02 (2.1x50 mm, 3 µm), with six stable isotopes and one analog as an internal standard. The overall turnaround time of the assay was 5 minutes. All the drugs tested (piperacillin, cefoperazone, meropenem, levofloxacin, moxifloxacin, daptomycin, linezolid, vancomycin, fluconazole and voriconazole) were linear in the test concentration range (r ≥ 0.9900), the accuracy was 95 %-111 %, the precision variation coefficient was greater than or equal to 10 %, the lower limit of quantitation was 0.31-7.51 mg/L, and the coefficient of variation of the matrix factor was less than 10 %. The recovery rates ranged from 85 % to 115 %, and the antibiotics were stable at 4°C and -20°C for 6 days, with an offset of greater than or equal to 15 %. This method was successfully applied to routine TDM in 252 elderly critically ill patients.